Get the Daily Brief
Latest Biotech News
EMA CHMP turns positive on Sanofi’s MS therapy while diverging on an FDA setback
EMA’s CHMP recommended approval of Sanofi’s BTK inhibitor Cenrifki (tolebrutinib) for secondary progressive multiple sclerosis at its April meeting, following a different outcome on the U.S. side....
Lanifibranor readout outlook drives leadership changes at Inventiva
Inventiva added senior leadership to its C-suite as it prepares for a Phase III readout for lanifibranor in metabolic dysfunction-associated steatohepatitis (MASH) expected in 4Q26. The company...
AI-enhanced microscopy enables sharper real-time imaging inside live cells
Researchers at the University of California San Diego reported an AI-enhanced microscopy workflow that delivers crisper, real-time video of events occurring inside living cells. The method is...
New fluorescent tool maps centrioles and cilia in living cells
EPFL researchers introduced CenSpark, a fluorescent probe designed to visualize centrioles and cilia inside living cells across species. The tool aims to make it easier to study structures central...
Engineering glycocalyx on adoptive cell therapies for B lymphoma
A new study in Engineering describes approaches to glycocalyx engineering for adoptive cell therapies targeting B lymphoma. The report frames glycocalyx modification as a way to address...
Neural circuit screening links TRPV4 to aminoglycoside hearing toxicity
Researchers reported evidence that TRPV4 drives aminoglycoside ototoxicity without reducing antimicrobial efficacy. The study highlights a mechanism in which the TRPV4 channel influences both...
More validation for MS-like mouse model driven by B cells and TH17
A study clarified how B cells and T helper 17 (TH17) cells contribute to experimental autoimmune encephalomyelitis, the commonly used mouse model for multiple sclerosis. The work addresses a...
Synthetic control arms spotlight alternative trial design for harder-to-study diseases
A Qureight innovation spotlight lays out how synthetic control arms use external datasets to compare treatment effects, aiming to reduce dependence on traditional placebo-controlled designs. The...
Regulatory: EMA CHMP positions for MS and dyslipidemia
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Sanofi’s BTK inhibitor Cenrifki (tolebrutinib) for secondary progressive multiple...
Deals: New takeover terms emerge for Seer
An investor group led by Bradley Radoff and Michael Torok raised its proposed Seer takeover price to $2.35 per share plus a contingent value right, according to an SEC filing referenced in the...
C-suite: Inventiva refreshes leadership ahead of Phase III readout
Inventiva added three executives to its C-suite as the French biotech prepares for a Phase III readout in 4Q26 for lanifibranor in metabolic dysfunction-associated steatohepatitis (MASH)....
Funding: Kurma closes €215M fund for disruptive therapeutics
Kurma Partners closed a €215M venture capital fund, described as its fourth and largest, targeting disruptive therapeutic solutions. The report notes prior Kurma exits including acquisitions of...
Clinical platform: Synthetic control arms gain momentum in trial design
A new data-driven approach is gaining traction in clinical development: synthetic control arms that use external datasets to generate comparator groups. The innovation spotlight described how...
Immunotherapy & engineered cells: Glycocalyx engineering for B-cell lymphoma ACT
A new study in Engineering outlines live-cell glycocalyx engineering strategies aimed at improving adoptive cell therapies (ACTs) for B-cell lymphoma. The work focuses on addressing recurring ACT...
Neuro/immune drug discovery: BBB-penetrant autophagy enhancers via AI screening
DeepDrugDiscovery unveiled an AI-driven screening platform designed to identify autophagy enhancers that can cross the blood-brain barrier and target Alzheimer’s disease pathology. The report...
Oncology biology: Epigenetic vulnerability in KMT2C/D loss
Research highlighted a set of actionable weaknesses created by loss of KMT2C and KMT2D, epigenetic regulators involved in tumor differentiation and fate control. The report ties the findings to...
Infectious disease: AI framework quantifies TB antibiotic resistance and predicts treatment response
Researchers introduced a convolutional neural network (CNN) approach intended to quantify antibiotic resistance in Mycobacterium tuberculosis and predict patient treatment responses. The report...
Diagnostics: Smart finger-cuff algorithm improves aortic stenosis case detection in Black patients
A REACH Trial report presented high accuracy for a smart finger cuff algorithm detecting moderate-to-severe aortic stenosis among African American patients. The work was presented at SCAI 2026...
Regulatory approvals in multiple sclerosis
Europe’s regulator moved to support Sanofi’s multiple sclerosis franchise after the U.S. FDA rejected the drug. The EMA’s CHMP recommended approval of Cenrifki (tolebrutinib) for non-relapsing...
FDA accelerates review of psychedelic mental health drugs
The FDA moved to speed up reviews for multiple psychedelic therapies targeting major depressive disorder, PTSD, and treatment-resistant depression. The agency will use priority review vouchers...